Healthcare - Biotechnology - NASDAQ - US
$ 1.78
2.3 %
$ 688 M
Market Cap
-0.56
P/E
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.[ Read More ]
The intrinsic value of one HUMAW stock under the base case scenario is HIDDEN Compared to the current market price of 1.78 USD, Humacyte, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart HUMAW
FINANCIALS
0
REVENUE
-100 M
OPERATING INCOME
-111 M
NET INCOME
-73.3 M
OPERATING CASH FLOW
-173 K
INVESTING CASH FLOW
4.51 M
FINANCING CASH FLOW
0
REVENUE
-30.2 M
OPERATING INCOME
-128 M
NET INCOME
-71.3 M
OPERATING CASH FLOW
-1.51 M
INVESTING CASH FLOW
63.3 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Humacyte, Inc.
| Current Assets | 83.3 M |
| Cash & Short-Term Investments | 80.4 M |
| Receivables | 0 |
| Other Current Assets | 2.83 M |
| Non-Current Assets | 44.9 M |
| Long-Term Investments | 0 |
| PP&E | 44.9 M |
| Other Non-Current Assets | 0 |
| Current Liabilities | 18.4 M |
| Accounts Payable | 6.49 M |
| Short-Term Debt | 5.23 M |
| Other Current Liabilities | 6.73 M |
| Non-Current Liabilities | 96.2 M |
| Long-Term Debt | 54.9 M |
| Other Non-Current Liabilities | 41.3 M |
EFFICIENCY
Earnings Waterfall
Humacyte, Inc.
| Revenue | 0 |
| Cost Of Revenue | 76.6 M |
| Gross Profit | -76.6 M |
| Operating Expenses | 23.5 M |
| Operating Income | -100 M |
| Other Expenses | 10.7 M |
| Net Income | -111 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-817.78%
ROE
-86.39%
ROA
-182.70%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Humacyte, Inc.
| Net Income | -111 M |
| Depreciation & Amortization | 7.72 M |
| Capital Expenditures | -2.28 M |
| Stock-Based Compensation | 6.83 M |
| Change in Working Capital | 6.57 M |
| Others | 18.1 M |
| Free Cash Flow | -75.6 M |
Wall Street Analysts Price Targets
Humacyte, Inc.
HUMAW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Humacyte, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 14, 2023
|
Sell 5.56 M USD
|
Niklason Laura E
President, CEO and Director |
- 2000000
|
2.78 USD |
|
1 year ago
Sep 14, 2023
|
Sell 5.56 M USD
|
Dougan Brady W
Director |
- 2000000
|
2.78 USD |
|
1 year ago
Aug 17, 2023
|
Sell 2.1 M USD
|
Niklason Laura E
President, CEO and Director |
- 570174
|
3.68 USD |
|
1 year ago
Aug 18, 2023
|
Sell 2.24 M USD
|
Niklason Laura E
President, CEO and Director |
- 626979
|
3.57 USD |
|
1 year ago
Aug 21, 2023
|
Sell 2.04 M USD
|
Niklason Laura E
President, CEO and Director |
- 602443
|
3.39 USD |
|
1 year ago
Aug 17, 2023
|
Sell 2.1 M USD
|
Dougan Brady W
Director |
- 570174
|
3.68 USD |
|
1 year ago
Aug 18, 2023
|
Sell 2.24 M USD
|
Dougan Brady W
Director |
- 626979
|
3.57 USD |
|
1 year ago
Aug 21, 2023
|
Sell 2.04 M USD
|
Dougan Brady W
Director |
- 602443
|
3.39 USD |
|
1 year ago
Aug 17, 2023
|
Sell 2.1 M USD
|
Ayabudge LLC
10 percent owner |
- 570174
|
3.68 USD |
|
1 year ago
Aug 18, 2023
|
Sell 2.24 M USD
|
Ayabudge LLC
10 percent owner |
- 626979
|
3.57 USD |
|
1 year ago
Aug 21, 2023
|
Sell 2.04 M USD
|
Ayabudge LLC
10 percent owner |
- 602443
|
3.39 USD |
|
1 year ago
Jun 15, 2023
|
Sell 1.56 M USD
|
Niklason Laura E
President, CEO and Director |
- 500000
|
3.1175 USD |
|
1 year ago
Jun 15, 2023
|
Sell 1.56 M USD
|
Dougan Brady W
director, 10 percent owner: |
- 500000
|
3.1175 USD |
|
1 year ago
Jun 15, 2023
|
Sell 1.56 M USD
|
Ayabudge LLC
10 percent owner |
- 500000
|
3.1175 USD |
|
1 year ago
Jun 13, 2023
|
Sell 12.7 M USD
|
Niklason Laura E
President, CEO and Director |
- 4875000
|
2.6 USD |
|
1 year ago
Jun 13, 2023
|
Sell 12.7 M USD
|
Dougan Brady W
director, 10 percent owner: |
- 4875000
|
2.6 USD |
|
1 year ago
Jun 13, 2023
|
Sell 12.7 M USD
|
Ayabudge LLC
10 percent owner |
- 4875000
|
2.6 USD |
|
1 year ago
May 25, 2023
|
Sell 7.22 M USD
|
Niklason Laura E
President, CEO and Director |
- 2625000
|
2.75 USD |
|
1 year ago
May 25, 2023
|
Sell 36.8 K USD
|
Prichard Heather Ledbetter
Chief Operating Officer |
- 9613
|
3.83 USD |
|
1 year ago
May 24, 2023
|
Sell 57.1 K USD
|
Prichard Heather Ledbetter
Chief Operating Officer |
- 13789
|
4.14 USD |
|
1 year ago
May 25, 2023
|
Sell 7.22 M USD
|
Dougan Brady W
director, 10 percent owner: |
- 2625000
|
2.75 USD |
|
1 year ago
May 25, 2023
|
Sell 7.22 M USD
|
Ayabudge LLC
10 percent owner |
- 2625000
|
2.75 USD |
|
1 year ago
May 18, 2023
|
Bought 19.9 K USD
|
Constantino Michael T.
Director |
+ 4750
|
4.18 USD |
|
1 year ago
Dec 16, 2022
|
Bought 52 K USD
|
Sander Dale A.
CFO and Chief Corp. Deve. Off. |
+ 20000
|
2.6 USD |
|
1 year ago
Dec 15, 2022
|
Bought 25.4 K USD
|
Niklason Laura E
President, CEO and Director |
+ 10000
|
2.54 USD |
|
1 year ago
Dec 15, 2022
|
Bought 25.4 K USD
|
Dougan Brady W
Director |
+ 10000
|
2.54 USD |
|
1 year ago
Dec 16, 2022
|
Sell 606 K USD
|
Niklason Laura E
President, CEO and Director |
- 239538
|
2.53 USD |
|
1 year ago
Dec 16, 2022
|
Sell 606 K USD
|
Dougan Brady W
Director |
- 239538
|
2.53 USD |
|
1 year ago
Dec 16, 2022
|
Sell 606 K USD
|
Ayabudge LLC
Director |
- 239538
|
2.53 USD |
|
1 year ago
Dec 13, 2022
|
Bought 15.4 K USD
|
Scheessele William John
Chief Commercial Officer |
+ 5000
|
3.09 USD |
|
1 year ago
Dec 13, 2022
|
Sell 937 K USD
|
Niklason Laura E
President, CEO and Director |
- 330000
|
2.84 USD |
|
1 year ago
Dec 14, 2022
|
Sell 763 K USD
|
Niklason Laura E
President, CEO and Director |
- 276304
|
2.76 USD |
|
1 year ago
Dec 15, 2022
|
Sell 246 K USD
|
Niklason Laura E
President, CEO and Director |
- 93426
|
2.63 USD |
|
1 year ago
Dec 13, 2022
|
Sell 937 K USD
|
Dougan Brady W
Director |
- 330000
|
2.84 USD |
|
1 year ago
Dec 14, 2022
|
Sell 763 K USD
|
Dougan Brady W
Director |
- 276304
|
2.76 USD |
|
1 year ago
Dec 15, 2022
|
Sell 246 K USD
|
Dougan Brady W
Director |
- 93426
|
2.63 USD |
|
1 year ago
Dec 13, 2022
|
Sell 937 K USD
|
Ayabudge LLC
Director |
- 330000
|
2.84 USD |
|
1 year ago
Dec 14, 2022
|
Sell 763 K USD
|
Ayabudge LLC
Director |
- 276304
|
2.76 USD |
|
1 year ago
Dec 15, 2022
|
Sell 246 K USD
|
Ayabudge LLC
Director |
- 93426
|
2.63 USD |
|
2 years ago
Sep 15, 2022
|
Bought 8.28 K USD
|
Niklason Laura E
President, CEO and Director |
+ 2000
|
4.14 USD |
|
2 years ago
Sep 15, 2022
|
Bought 8.28 K USD
|
Dougan Brady W
director, 10 percent owner: |
+ 2000
|
4.14 USD |
|
2 years ago
Sep 15, 2022
|
Sell 6.09 M USD
|
Niklason Laura E
President, CEO and Director |
- 1522500
|
4 USD |
|
2 years ago
Sep 15, 2022
|
Sell 6.09 M USD
|
Dougan Brady W
director, 10 percent owner: |
- 1522500
|
4 USD |
|
2 years ago
Sep 15, 2022
|
Sell 6.09 M USD
|
Ayabudge LLC
10 percent owner |
- 1522500
|
4 USD |
|
2 years ago
Dec 14, 2021
|
Sell 232 K USD
|
Dougan Brady W
director, 10 percent owner: |
- 23694
|
9.798 USD |
|
2 years ago
Dec 14, 2021
|
Sell 712 K USD
|
Dougan Brady W
director, 10 percent owner: |
- 76306
|
9.325 USD |
|
2 years ago
Dec 15, 2021
|
Sell 1.11 M USD
|
Dougan Brady W
director, 10 percent owner: |
- 125000
|
8.885 USD |
|
2 years ago
Dec 16, 2021
|
Sell 675 K USD
|
Dougan Brady W
director, 10 percent owner: |
- 75000
|
9 USD |
|
2 years ago
Dec 14, 2021
|
Sell 232 K USD
|
Niklason Laura E
President, CEO and Director |
- 23694
|
9.798 USD |
|
2 years ago
Dec 14, 2021
|
Sell 712 K USD
|
Niklason Laura E
President, CEO and Director |
- 76306
|
9.325 USD |
|
2 years ago
Dec 15, 2021
|
Sell 1.11 M USD
|
Niklason Laura E
President, CEO and Director |
- 125000
|
8.885 USD |
|
2 years ago
Dec 16, 2021
|
Sell 675 K USD
|
Niklason Laura E
President, CEO and Director |
- 75000
|
9 USD |
|
2 years ago
Nov 22, 2021
|
Bought 24.8 K USD
|
Constantino Michael T.
Director |
+ 2300
|
10.7912 USD |
|
2 years ago
Nov 22, 2021
|
Bought 2.17 K USD
|
Constantino Michael T.
Director |
+ 200
|
10.83 USD |
|
3 years ago
Aug 26, 2021
|
Bought 15.2 M USD
|
Niklason Laura E
President, CEO and Director |
+ 1522500
|
10 USD |
|
3 years ago
Aug 26, 2021
|
Bought 15.2 M USD
|
Dougan Brady W
director, 10 percent owner: |
+ 1522500
|
10 USD |
|
3 years ago
Aug 26, 2021
|
Bought 15.2 M USD
|
Ayabudge LLC
10 percent owner |
+ 1522500
|
10 USD |
7. News
8. Profile Summary
Humacyte, Inc. HUMAW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 688 M
Dividend Yield
0.00%
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Contact
None
IPO Date
None
Employees
183
Officers
Mr. William John Scheessele
Chief Commercial Officer
Ms. Sabrina Osborne GPHR, SPHR
Chief People Officer
Dr. Shamik J. Parikh M.D.
Chief Medical Officer
Mr. Harold Alterson
Chief Quality Officer
Dr. Yang Cao M.D., Ph.D.
Chief Regulatory Officer
Dr. Laura E. Niklason M.D., Ph.D.
Founder, President, Chief Executive Officer & Director
Mr. Dale A. Sander
Chief Financial Officer, Chief Corporate Development Officer & Treasurer
Dr. Heather Ledbetter Prichard Ph.D.
Chief Operating Officer